ABP-7
The actin-binding peptide domain from Thymosin Beta-4 that specifically sequesters G-actin monomers, inhibiting actin polymerisation and modulating cell motility - studied for wound healing and immune modulation.
Community Rating
No ratings yet
Compound Profile
ABP-7
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. ABP-7 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Sequestrates G-actin (globular actin) monomers - prevents polymerisation into F-actin filaments
- Modulates cell cytoskeleton and cell motility - relevant for wound healing research
- Isolated functional domain from Thymosin Beta-4 (TB-500) - the actin-binding component
- ABP-7 is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Sequestrates G-actin (globular actin) monomers - prevents polymerisation into F-actin filaments
- Modulates cell cytoskeleton and cell motility - relevant for wound healing research
- Isolated functional domain from Thymosin Beta-4 (TB-500) - the actin-binding component
- Influences cell migration and shape adaptation through cytoskeletal remodelling
In Plain English
Simple summaryABP-7 is a synthetic antimicrobial peptide derived from the active region of whey protein-derived beta-lactoglobulin, developed for cosmetic applications -- primarily to provide in-formulation preservation and mild skin surface antimicrobial activity against acne-causing bacteria (Cutibacterium acnes, Staphylococcus epidermidis) without the irritation or resistance development concerns of benzoyl peroxide and antibiotics. As a cationic peptide, it disrupts bacterial membranes through electrostatic interaction, killing bacteria by a physical mechanism that doesn't generate resistance in the same way that enzymatic antibiotic targets do. Some formulations position it as both a cosmetic preservative booster and a mild acne-control active.
- Sequestrates G-actin (globular actin) monomers - prevents polymerisation into F-actin filaments
- Modulates cell cytoskeleton and cell motility - relevant for wound healing research
- Isolated functional domain from Thymosin Beta-4 (TB-500) - the actin-binding component
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is ABP-7?
Tap any underlined term for an instant definition.
ABP-7 (Actin-Binding Peptide-7) is the actin-binding domain peptide derived from Thymosin Beta-4 (TB4), the endogenous G-actin sequestering protein that is the active component of the widely-studied research peptide TB-500. While TB-500 represents the entire Thymosin Beta-4 molecule, ABP-7 isolates the specific peptide sequence responsible for TB4's primary biochemical function: binding to globular actin (G-actin) monomers and preventing their polymerisation into filamentous actin (F-actin).
The actin cytoskeleton is one of the most important structural systems in animal cells. Actin exists in two forms that are in dynamic equilibrium: G-actin (the globular monomer) and F-actin (the filamentous polymer formed by polymerisation of G-actin). The balance between G-actin and F-actin determines cell shape, rigidity, motility, and the ability to generate contractile forces. This balance is regulated by numerous actin-binding proteins, of which Thymosin Beta-4 is one of the most abundant in many cell types.
By sequestering G-actin monomers, ABP-7 (and by extension TB4) reduces the pool of actin available for filament formation. This actin sequestration has complex downstream effects: cells with less F-actin are more motile (since actin network disassembly precedes cell front extension), cytoskeletal architecture is altered (affecting cell shape and mechanosensing), and signalling pathways that use actin dynamics as inputs (including Rho-GTPase signalling and nuclear mechanotransduction) are modified.
The wound healing relevance of actin sequestration stems from the critical importance of cell motility in wound closure. Wound healing requires keratinocytes and fibroblasts to migrate into the wound bed - a process that depends on coordinated actin polymerisation at the leading edge (forming lamellipodia and filopodia) and depolymerisation at the trailing edge. Modulating this cycle through actin sequestration can influence the speed and efficiency of cell migration and wound closure.
As a research tool, ABP-7 provides a more targeted means of studying actin biology than using TB-500 (which has additional activities including interactions with other proteins). The isolated actin-binding domain allows researchers to attribute observed effects specifically to actin sequestration rather than other TB4 activities.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on ABP-7. See all Healing & Recovery peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
ABP-7 research doses are derived from preclinical studies. Human dosing has not been established.
Preclinical reference: doses comparable to TB-500 studies when administered as isolated domain Research context: wound healing models, cell motility assays, actin dynamics studies
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute lyophilised ABP-7 with bacteriostatic water. Administer subcutaneously or apply topically to wound area depending on research protocol design.
What the research doesn't show
ABP-7 has limited published human clinical evidence for acne treatment -- most data is in vitro antimicrobial activity testing. The physical membrane disruption mechanism is genuinely less resistance-prone than antibiotic mechanisms, but translating in vitro minimum inhibitory concentrations to effective skin surface concentrations in real acne treatment is a step that's not independently validated for this specific peptide.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain ABP-7, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
ABP-7 has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: sequestrates g-actin (globular actin) monomers - prevents polymerisation into f-actin filaments.
The most commonly reported side effect in research subjects is limited human safety data. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
LL-37 is the benchmark human antimicrobial peptide with the broadest published activity spectrum, but it's not practical for cosmetic formulation. Benzoyl peroxide is the most effective OTC acne antimicrobial with decades of clinical evidence. Niacinamide reduces sebum production and has anti-inflammatory effects relevant to acne. ABP-7 occupies a gentler, resistance-resistant niche between prescription treatments and standard OTC options.
Compare ABP-7 side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.